Piper Sandler Upgrades Akebia Therapeutics (AKBA)
Fintel reports that on May 31, 2023, Piper Sandler upgraded their outlook for Akebia Therapeutics (NASDAQ:AKBA) from Neutral to Overweight . Analyst Price Forecast Suggests 112.81% Upside As of May 11, 2023, the average one-year price target for Akebia Therapeutics is 2.04. The forecasts range from a low of 2.02…
bubmagMay 31, 2023